It is the policy of The University of Alabama that investigators who hold investigational new drugs (IND) or investigational device exemptions (IDE) will follow the Food and Drug Administration’s requirements for sponsors. Below is a list of those regulations.

For drugs or devices:

- 21 CFR §11 (Electronic records and electronic signature)
- 21 CFR §54 (Financial Disclosure by Clinical Investigators) [FDA forms 3454 and 3455]

For drugs and biologics only:

- 21 CFR §210 (Current Good Manufacturing Practice in Manufacturing, Processing, Packing Or Holding of Drug; General)
- 21 CFR §312 (Investigational New Drug Application)
- 21 CFR §314 (Drugs for Human Use)
- 21 CFR §320 (Bioavailability and Bioequivalence Requirements)
- 21 CFR §330 (Over-The-Counter (OTC) Human Drugs Which are Generally Recognized as Safe and Effective and Not Misbranded)
- 21 CFR §601 (Biologics Licensing)

For devices only:

- 21 CFR §812 (Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices)
- 21 CFR §812 (Investigational Device Exemptions)
- 21 CFR §814 (Premarket Approval of Medical Devices)
- 21 CFR §820 (Quality System Regulation)
- 21 CFR §860 (Medical Device Classification Procedures)